Because it is a growth factor receptor, anti-HER2 antibody-based therapeutics can inhibit tumor cell growth by downregulating proliferative pathways as well by redirecting immune cells or delivering cytotoxic payloads (Smith et al., 2022). This evidence concerns the gene ERBB2 and neoplasm.